0001127602-12-006385.txt : 20120216 0001127602-12-006385.hdr.sgml : 20120216 20120216162950 ACCESSION NUMBER: 0001127602-12-006385 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120214 FILED AS OF DATE: 20120216 DATE AS OF CHANGE: 20120216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CLACKSON TIMOTHY P CENTRAL INDEX KEY: 0001242992 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21696 FILM NUMBER: 12619707 MAIL ADDRESS: STREET 1: C/O ARIAD PHARMACEUTICALS INC STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARIAD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884731 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 223106987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174940400 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 form4.xml PRIMARY DOCUMENT X0304 4 2012-02-14 0000884731 ARIAD PHARMACEUTICALS INC ARIA 0001242992 CLACKSON TIMOTHY P C/O ARIAD PHARMACEUTICALS INC 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 1 President, R&D, CSO Common Stock 2012-02-14 4 M 0 18385 4.05 A 138267 D Common Stock 2012-02-14 4 M 0 41551 4.19 A 179818 D Common Stock 2012-02-14 4 M 0 16500 3.90 A 196318 D Common Stock 2012-02-14 4 S 0 76436 15.1209 D 119882 D Employee Stock Option (Right to Buy) 4.05 2012-02-14 4 M 0 18385 0 D 2003-06-13 2012-06-13 Common Stock 18385 6615 D Employee Stock Option (Right to Buy) 4.19 2012-02-14 4 M 0 41551 0 D 2003-06-18 2012-06-18 Common Stock 41551 8449 D Employee Stock Option (Right to Buy) 3.90 2012-02-14 4 M 0 16500 0 D 2004-08-15 2013-08-15 Common Stock 16500 16500 D Shares were acquired upon the exercise of outstanding stock options at $4.05 per share. Shares were acquired upon the exercise of outstanding stock options at $4.19 per share. Shares were acquired upon the exercise of outstanding stock options at $3.90 per share. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2011. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.98 to $15.25, inclusive. The reporting person undertakes to provide to ARIAD Pharmaceuticals, Inc. ("ARIAD"), any security holder of ARIAD, or the staff of the Security and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/Edward M. Fitzgerald, Attorney-in-Fact 2012-02-16